This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

FTC sues AndroGel drugmakers for unlawfully keeping a generic version off the market

( September 8, 2014, 16:49 GMT | Official Statement) -- MLex Summary: The US Federal Trade Commission filed a complaint charging AbbVie, Abbott Laboratories, Unimed Pharmaceuticals, Besins Healthcare, and Teva Pharmaceuticals for unlawfully attempting to keep generic versions of the testosterone replacement drug AndroGel off the market. The FTC alleges that the companies filed baseless patent infringement lawsuits against potential generic rivals and then entered into a pay-for-delay agreement with Teva Pharmaceuticals to further hinder generic drug competition.See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections